IBB
iShares Biotechnology ETF
The largest biotechnology ETF tracking the ICE Biotechnology Index. High risk/reward profile with exposure to drug development pipelines. More concentrated and volatile than broad healthcare (XLV). Pairs with XBI for different biotech weighting approaches.
TER
0.44%
AUM
$6B
Holdings
~270
Data Range
— → —
Key Facts
ISIN
US4642875565
Issuer
BlackRock
Benchmark
ICE Biotechnology Index
Total Expense Ratio (TER)
0.44%
Assets Under Management
$6B approx.
Inception Date
2001-02-05
Domicile
US
Legal Structure
Open-End Fund
Dividend Policy
Distributing (pays dividends)
Replication Method
Physical (Full Replication)
UCITS Status
✗ Not UCITS
Fund Currency
USD
Primary Exchange
Nasdaq
Number of Holdings
~270
Equivalent ETFs
These ETFs track the same or very similar underlying index:
Who Is This ETF For?
✓General portfolio building block for the asset class it covers.
Key Risks to Consider
• Market risk: equity values can drop 30-50% in severe bear markets.
• Non-UCITS: may have unfavorable tax treatment for non-US investors (US estate tax, withholding tax).
Similar ETFs
Continue Your Analysis
Data & Methodology
Metadata sourced from official issuer documentation. Price data from Yahoo Finance (monthly adjusted close, includes reinvested dividends and splits). AUM figures are approximate and updated quarterly.
Data source: Yahoo Finance (IBB), iShares (metadata)Last verified: 2026-05-06